Please note, this OEL/ADE monograph also applies to procainamide hydrochloride (CAS RN 614-39-1), and procainamide sulfate (CAS RN 63887-34-3). Procainamide hydrochloride is indicated for the treatment of documented irregular abnormal heart beats. Procainamide allows various sections of the heart to have a longer rest period between beats, slows conduction, and increases the point at which these parts of the heart initiate a new heartbeat to achieve a better balance throughout the heart to produce a coordinated and effective normal heartbeat.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Procainamide, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.